卡维地洛治疗舒张性心力衰竭临床观察

Carvedilol on the management of diastolic heart failure

目的评价卡维地洛对舒张性心力衰竭的临床疗效和安全性。方法将53例舒张性心力衰竭患者随机分为治疗组27例及对照组26例,全部给予抗舒张性心力衰竭的常规治疗,治疗组加用卡维地洛5～40mg/d,疗程6个月。疗程结束后,对比两组患者治疗前、后临床症状和左心室超声收缩及舒张功能指标改善情况。结果治疗组总有效率及左心室舒张功能指标的改善均优于对照组(P<0.05、0.01)。治疗过程中,两组均发生部分轻度不良反应,无一例停药。结论应用卡维地洛可明显改善左室舒张功能,且安全、有效。

Objective To evaluate the effect and safety of carvedilol on treatment of diastolic heart failure. Methods 53 eases were randomized to treatment group （27 cases） or control group （26 cases）. Both the two groups received routine therapy for diastolic heart failure. The treatment group were added earvedilol of 5.0 to 40.0 mg/d. The course of the treatment was 6 months. After that, the clinical symptom and the index of the left ventricle systolic and diastolic function in eehoeardiography of the two groups were compared. Results Both the rate of effective and the index of the left ventricle diastolic function in the treatment group were better than that of the control group （P〈0.05, 0.01 respectively）. Some patients in two groups presented with mild side effects during follow up, but no one stopped therapy. Conclusion Adding carvedilol to the routine therapy is safe and effective to treat diastolic heart failure. It can improve the left ventricle diastolic function obviously.